NCT07783542Phase 2Recruiting

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Study sponsor: Oruka Therapeutics, Inc. · ORKA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-10Estimated
Enrollment · participants200Estimated
Source updated2026-10-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.